Viewing Study NCT02910700

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 12:14 PM
Ignite Modification Date: 2026-02-24 @ 2:08 PM
Study NCT ID: NCT02910700
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-17
First Post: 2016-09-20
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
Sponsor: M.D. Anderson Cancer Center
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Malignant Neoplasm in the Brain View
None Metastatic Melanoma View
None Stage III Cutaneous Melanoma AJCC v7 View
None Stage IIIA Cutaneous Melanoma AJCC v7 View
None Stage IIIB Cutaneous Melanoma AJCC v7 View
None Stage IIIC Cutaneous Melanoma AJCC v7 View
None Stage IV Cutaneous Melanoma AJCC v6 and v7 View
None Unresectable Melanoma View
Keywords: